raloxifene hydrochloride has been researched along with Carcinoma, Endometrioid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, W; Li, S; Qiu, H; Wang, Y; Yu, J | 1 |
| Hisamatsu, T; Ito, K; Kamiura, S; Kimura, T; Mabuchi, S; Morishige, K; Nakamura, K; Nishio, Y; Sawada, K; Sugiyama, M | 1 |
1 trial(s) available for raloxifene hydrochloride and Carcinoma, Endometrioid
| Article | Year |
|---|---|
Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial.
Topics: Adult; Aged; Bone and Bones; Bone Density; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hydroxycholecalciferols; Hysterectomy; Lipids; Middle Aged; Postmenopause; Postoperative Complications; Raloxifene Hydrochloride; Treatment Outcome | 2015 |
1 other study(ies) available for raloxifene hydrochloride and Carcinoma, Endometrioid
| Article | Year |
|---|---|
RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Endometrioid; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression; Humans; Inhibitory Concentration 50; Lymphatic Metastasis; Mice; Mice, SCID; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Raloxifene Hydrochloride; Tumor Burden; Up-Regulation | 2014 |